Paolo Strati
M.D. Anderson Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Paolo Strati as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 16:55 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06285825 · A Pilot Study of Emapalumab for the Treatment of CAR T-Cell Therapy-Associated Prolonged CytopeniaM.D. Anderson Cancer Center · recruiting · Cytopenia · principal investigator
- Ph2NCT05929716 · An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell LymphomaM.D. Anderson Cancer Center · withdrawn · Large B-cell Lymphoma, B-cell Lymphoma · principal investigator
- Ph2NCT05464719 · A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell TherapyM.D. Anderson Cancer Center · recruiting · Large B-cell Lymphoma, Lymphoma · principal investigator
- Ph1/Ph2NCT05025800 · ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin LymphomaM.D. Anderson Cancer Center · active not recruiting · Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular Lymphoma · principal investigator
- Ph2NCT04432506 · Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell LymphomaM.D. Anderson Cancer Center · completed · Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent High Grade B-Cell Lymphoma · principal investigator
- Ph2NCT04404088 · Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular LymphomaM.D. Anderson Cancer Center · recruiting · Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular Lymphoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 16:55 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Targeting Myeloid Cells to Mitigate Immune Effector Cell-Associated Neurotoxicity Syndrome in Large B-cell LymphomaR21CA259694 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2021 · $378,675 awarded in 2021Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 16:55 UTC. The ranking covers the 200 most relevant of 38 PubMed records, and a shared surname and initials can bring in a namesake. All 38 on PubMed
- Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome.Am J Hematol · 2015137 citationsRCR 3.7
- 137 citationsRCR 29.3
- Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL.Blood · 2014124 citationsRCR 3.4
- Renal complications in chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis: the Mayo Clinic experience.Haematologica · 201575 citationsRCR 2.8
- 65 citationsRCR 2.1
- 64 citationsRCR 13.7
- Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia.Blood · 201357 citationsRCR 1.4
- A phase 1 study of prophylactic anakinra to mitigate ICANS in patients with large B-cell lymphoma.Blood Adv · 202346 citationsRCR 3.5
- 42 citationsRCR 1.3
- A phase 2, multicentre, open-label trial (ACE-LY-003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma.Br J Haematol · 202234 citationsRCR 2.2